Multiple sclerosis (MS) is the most common neurological immune-mediated disease leading
to disability in young adults. The outcome of the disease is unpredictable, and over time …

The potent pleiotropic lipid mediator sphingosine-1-phosphate (S1P) participates in
numerous cellular processes, including angiogenesis and cell survival, proliferation, and …

Patients with multiple sclerosis acquire disability either through relapse-associated
worsening (RAW) or progression independent of relapse activity (PIRA). This study …

These updated EBMT guidelines review the clinical evidence, registry activity and
mechanisms of action of haematopoietic stem cell transplantation (HSCT) in multiple …

Purpose of review This review presents a comprehensive analysis of the current high-
efficacy disease-modifying therapies (DMTs) available for treatment of multiple sclerosis …

Objective To assess real‐world effectiveness of initial treatment with newer compared to
injectable disease‐modifying therapies (DMTs) on disease activity in pediatric multiple …

Randomized controlled trials are the gold standard to investigate efficacy and safety of new
treatments. In certain settings, however, randomizing patients to control may be difficult for …

The treatment of multiple sclerosis (MS), the most common chronic inflammatory,
demyelinating and neurodegenerative disease of the central nervous system (CNS) …

Fingolimod (Gilenya) received regulatory approval from the US FDA in 2010 as the first-in-
class sphingosine 1-phosphate (S1P) receptor (S1PR) modulator and was the first oral …

The Canadian Multiple Sclerosis Working Group has updated its treatment optimization
recommendations (TORs) on the optimal use of disease-modifying therapies for patients …